Chemiluminescence technique for measuring reactive oxygen species
Rutman uses compounded Semaglutide because it offers a lower cost than more expensive brand name options
Common short-acting GLP-1s include exenatide, liraglutide, and lixisenatide
Compared to liraglutide, which requires daily injections and typically results in more modest weight loss, semaglutide offers a more convenient weekly dosing schedule and greater reductions in body weight
For example, in December 2024, Novo Nordisk bought three Catalent sites for US$11bn in order to boost its injectable drug capacity, and in December 2025, Eli Lilly announced new plans to build a US$6bn manufacturing facility in the US
Summary of the standardized set of Patient-Reported Outcome Measures (PROMs) and Patient-Reported Experience Measures (PREMs) proposed by the NAVETA Obesity Expert Committee